Boswellia (AKBA) vs PEA
A side-by-side research comparison of Boswellia (AKBA) and PEA across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Boswellia (AKBA) | PEA |
|---|---|---|
| Full name | Boswellia Serrata Extract (AKBA) | Palmitoylethanolamide |
| Category | Pain & Inflammation | Pain & Inflammation |
| Status | OTC supplement | Dietary supplement (medical food in EU) |
| Mechanism | AKBA (acetyl-11-keto-beta-boswellic acid) selectively inhibits 5-lipoxygenase (5-LOX), reducing pro-inflammatory leukotrienes. This targets a different inflammatory pathway than NSAIDs (which act on COX), sparing the stomach lining. | Activates PPARĪ± nuclear receptors for anti-inflammatory gene transcription. Inhibits mast cell degranulation. Enhances endocannabinoid tone by inhibiting FAAH (increasing anandamide). Desensitizes TRPV1 pain channels via allosteric modulation. |
| Molecular weight | 512.7 Da (AKBA) | 299.49 Da |
| Half-life | ~6 hours (AKBA) | ~1-2 hours (micronized form extends effects) |
| Bioavailability | Low; improved by AKBA-standardized and phytosome forms | ~20% (standard); improved with micronized/ultra-micronized forms |
| Typical dose | 100-250 mg AKBA-standardized, 1-2x daily | 300-1200 mg |
| Frequency | 1-2x daily | 2-3x daily |
| Route | Oral capsule | Oral (micronized preferred) |
Boswellia (AKBA) reported benefits
- Reduces joint pain and stiffness
- Non-NSAID (stomach-sparing) anti-inflammatory
- Supports gut inflammation (IBD research)
- Cartilage protection
- Anti-inflammatory via 5-LOX inhibition
PEA reported benefits
- Chronic pain reduction
- Neuropathic pain relief
- Anti-inflammatory (mast cell stabilization)
- No tolerance or dependence
- Neuroprotection
- Safe with other medications
Related comparisons
Research and educational reference only. Not medical advice.